Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTPNGDE)

• DTT Name: Prostaglandin E2 receptor EP3 (PTGER3) DTT Info
• Gene Name: PTGER3

Molecule-Related Drug & Molecule List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[1]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[2]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[1]

1 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[3]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DG041	DMVO9WM	Peripheral vascular disease	BD4Z	Discontinued in Phase 2	[4]
GR-63799X	DM13GK8	Asthma	CA23	Discontinued in Phase 1	[5]

31 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
11-deoxy-PGE1	DM1ERJC	Discovery agent	N.A.	Investigative	[6]
17-phenyl-omega-trinor-PGE2	DM9OMI3	Discovery agent	N.A.	Investigative	[1]
3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid	DM8P26J	Discovery agent	N.A.	Investigative	[7]
3-(2-(4-methoxycinnamyl)phenyl)acrylic acid	DM61CHU	Discovery agent	N.A.	Investigative	[7]
3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid	DM9O5CH	Discovery agent	N.A.	Investigative	[7]
3-(2-cinnamylphenyl)acrylic acid	DM4XWME	Discovery agent	N.A.	Investigative	[7]
AH6809	DMKN3R9	Discovery agent	N.A.	Investigative	[8]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[8]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[1]
cicaprost	DM7ZJ4H	Discovery agent	N.A.	Investigative	[1]
cloprostenol	DMH01JV	Discovery agent	N.A.	Investigative	[8]
fluprostenol	DM9Q2PG	Discovery agent	N.A.	Investigative	[8]
FR-181157	DM2V7U1	Discovery agent	N.A.	Investigative	[9]
I-BOP	DMJAPML	Discovery agent	N.A.	Investigative	[1]
isocarbacyclin	DMZR7W6	Discovery agent	N.A.	Investigative	[1]
L-798,106	DM4FMGJ	Discovery agent	N.A.	Investigative	[10]
L-826266	DMYJ6QZ	Discovery agent	N.A.	Investigative	[11]
M&B 28767	DMJQG82	Discovery agent	N.A.	Investigative	[1]
Molecule 21	DMA7T0N	Pain	MG30-MG3Z	Investigative	[12]
ONO-8713	DMD2G65	Discovery agent	N.A.	Investigative	[6]
ONO-AE-248	DMA7VP5	Discovery agent	N.A.	Investigative	[13]
ONO-AE1-329	DMS3MZG	Discovery agent	N.A.	Investigative	[14]
ONO-AE2-227	DM78DO6	Discovery agent	N.A.	Investigative	[15]
ONO-AE3-208	DMEY7T4	Discovery agent	N.A.	Investigative	[16]
ONO-AE3-240	DMN3OWP	Discovery agent	N.A.	Investigative	[17]
ONO-AE5-599	DMDA7M9	Discovery agent	N.A.	Investigative	[18]
ONO-AP-324	DMA1NL9	Discovery agent	N.A.	Investigative	[19]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[6]
SC46275	DM6AS0P	Discovery agent	N.A.	Investigative	[20]
STA2	DMIYJ2M	Discovery agent	N.A.	Investigative	[1]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[8]

References

• [1] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [2] IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
• [3] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [4] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [5] Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
• [6] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
• [7] Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42.
• [8] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [9] Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3284-7.
• [10] Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat. Br J Pharmacol. 2009 Sep;158(1):372-81.
• [11] Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol. 2011 Feb;162(4):863-79.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 342).
• [13] Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2141-7.
• [14] The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9.
• [15] Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32.
• [16] The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93.
• [17] Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003 Jan 20;197(2):221-32.
• [18] Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci. 2007 Jun 6;80(26):2446-53.
• [19] Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol. 1998 Nov;125(6):1288-96.
• [20] Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery. Prostaglandins Leukot Essent Fatty Acids. 2006 Jun;74(6):401-15.